ASBP logo

Aspire Biopharma Holdings, Inc. Stock Price

NasdaqCM:ASBP Community·US$10.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

ASBP Share Price Performance

US$0.11
-11.30 (-99.05%)
US$0.11
-11.30 (-99.05%)
Price US$0.11

ASBP Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with weak fundamentals.

5 Risks
0 Rewards

Aspire Biopharma Holdings, Inc. Key Details

US$1.9k

Revenue

US$1.1k

Cost of Revenue

US$884.0

Gross Profit

US$20.5m

Other Expenses

-US$20.5m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.19
45.54%
-1,058,156.83%
-75.2%
View Full Analysis

About ASBP

Founded
2021
Employees
n/a
CEO
Kraig Higginson
WebsiteView website
aspirebiolabs.com

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Recent ASBP News & Updates

Recent updates

No updates